With $55 billion earmarked to bolster its U.S. operations, Johnson & Johnson is the latest drugmaker to zero in on expansion plans that are aimed, at least in part, at abating the Trump administration’s pharmaceutical tariff threats. More: J&J fleshes
read moreAs Recipharm continues to refine its footprint, the CDMO is selling its development and small-scale active pharmaceutical ingredient (API) manufacturing facility in Yavne, Israel, to Scinai Immunotherapeutics. More: Recipharm focuses footprint with sale of Israel API plant, new CDMO partnership
read moreIn his report, Senator Bill Cassidy suggested a slate of changes to the FDA to support broader drug access and to reduce regulatory burdens on drugmakers. More: Senate HELP Committee chair pitches proposals for FDA reform Source: fierce
read moreLess than half a year after winning an inaugural green light in chronic hives, Novartis’ oral BTK inhibitor Rhapsido is jockeying to expand its urticaria reach into a new indication where it has the potential to become the first targeted
read moreStada will invest more than 85 million euros (around $101 million) to build a new production facility in Saudi Arabia, which will ultimately serve as a supply hub for the broader Middle East and North Africa region. The plant, which
read moreBayer has spent years working to get a handle on its Roundup legal mess. With a multibillion-dollar deal unveiled Tuesday, it’s moving a step closer to that goal. More: Bayer strikes .25B Roundup settlement, favoring 'speed and containment' of thorny
read more© 1994 - 2026 B.M. Pharmaceuticals